nVerses Capital’s Gilead Sciences GILD Stock Holding History

nVerses Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,793	Closed	-$529K	–	397
2026 Q1	$529K	Buy	+3,793	New	+$531K	0.48%	42
2024 Q4	–	Sell	-300	Closed	-$25.2K	–	339
2024 Q3	$25.2K	Buy	+300	New	+$22.9K	0.01%	769
2024 Q2	–	Sell	-200	Closed	-$14.7K	–	1079
2024 Q1	$14.7K	Buy	+200	New	+$15.4K	0.04%	448

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

nVerses Capital's GILD Position: Q2 2026 in Review

nVerses Capital sold out of Gilead Sciences (GILD) in Q2 2026, closing a stake of 3,793 shares — an estimated $529K sold.

nVerses Capital first reported a position in GILD in Q1 2024 and held it in 3 quarters. The position peaked at $529K in Q1 2026. 1,957 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

nVerses Capital reported no remaining Gilead Sciences position as of Q2 2026 after selling out during the quarter.
nVerses Capital sold 3,793 Gilead Sciences shares in Q2 2026, an estimated $529K.
nVerses Capital first reported a position in Gilead Sciences in Q1 2024 and held it in 3 quarters.
nVerses Capital's Gilead Sciences position peaked at $529K in Q1 2026.
1,957 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.